Hybio Pharmaceutical and Institute of Process Engineering, Chinese Academy of Sciences Enter into Strategic Cooperation to Jointly Establish "Innovation Consortium for Industrial Transformation of Hig
On August 20,2025, Shenzhen Hybio Pharmaceutical Co., Ltd. (referred to as "Hybio Pharmaceutical") and the Institute of Process Engineering, Chinese Academy of Sciences (referred to as "IPE-CAS") officially signed a strategic cooperation agreement to jointly build the "Innovation Consortium for Industrial Transformation of High-End Peptide Sustained-Release Preparations". Tang Yangming, Director and Vice President of Hybio Pharmaceutical, and Yan Xuehai, Vice Director of IPE-CAS, signed the agreement on behalf of both parties.
Academician Ma Guanghui of IPE-CAS, Huang Xiaowen, Director of the Science and Technology Cooperation Department of IPE-CAS, Ji Junjie, Director of the Industry Promotion Office of the Cooperation Department of IPE-CAS, Shen Guizhi, Associate Researcher of IPE-CAS; Zeng Shaogui, Chairman and President of Hybio Pharmaceutical, and Liu Xuejiao, Director of Business Development of Hybio Pharmaceutical, jointly witnessed the signing ceremony.
According to the agreement, this cooperation will give full play to Hybio Pharmaceutical’s leading advantages in industrialization scenarios, R&D innovation, and GMP large-scale production, while relying on IPE-CAS’s profound accumulation in cutting-edge technologies and basic research. Guided by the principle of "joint R&D, result sharing, and benefit win-win", the two parties will conduct in-depth cooperation covering the entire "industry-academia-research-application" chain of high-end peptide sustained-release preparations. Meanwhile, taking Hybio Pharmaceutical’s under-research weight-loss innovative drug HY3003 as a carrier, they will apply advanced peptide sustained-release technologies to focus on addressing key points of GLP-1 drugs in clinical application, such as administration frequency, gastrointestinal adverse reactions, and low-temperature transportation and storage, so as to promote the high-quality development of China’s Peptide Drug industry.
Four Cooperation Directions to Advance Simultaneously
Scientific and Technological Support: Conduct R&D on key technologies for high-end peptide sustained-release preparations to achieve major industry-leading innovative results, while advancing talent training, standard formulation, and transformation of scientific and technological achievements in parallel.
Joint Research for Breakthroughs: Establish a technical system for "liquid-liquid phase separation"-mediated precise process control assembly and large-scale production of high-uniformity sustained-release microspheres, providing strong technological support for the industrial transformation of high-end peptide sustained-release preparations.
Strategic Consulting & Academic Exchange: IPE-CAS will provide strategic consulting for Hybio Pharmaceutical in its transformation towards high-quality development through the development of innovative high-barrier preparations. The two parties will jointly organize experts and scholars to carry out academic exchanges, and work together to promote the academic development of new-type high-end peptide preparations in the industry.
Achievement Incubation & Talent Training: The two parties will jointly promote the transformation and application of scientific research achievements, and cultivate high-quality talents that meet the development needs of the industry.
Hybio Pharmaceutical stated： "Hybio Pharmaceutical has been deeply engaged in the peptide drug field for 27 years, accumulating rich experience in R&D innovation and quality control. We hope to leverage IPE-CAS’s profound accumulation in cutting-edge technologies and basic research to achieve breakthroughs in key technologies in the field of high-end peptide sustained-release preparations, and contribute to the development of China’s biopharmaceutical industry."
IPE-CAS said： "High-end peptide sustained-release preparations are an important development direction in the biopharmaceutical field, facing many technical challenges. Our research team in biomolecular assembly and engineering has accumulated rich experience in cutting-edge technologies, while Hybio Pharmaceutical has strong industrial transformation capabilities. The cooperation between the two parties will realize complementary advantages, jointly overcome technical bottlenecks, and provide solid technological support for the development of the industry."
In the future, the two parties will establish a multi-level communication and exchange mechanism to further expand the depth and breadth of information exchange, ensure efficient collaboration in all links including technology R&D, project advancement, and achievement transformation, and contribute more to the innovation and upgrading of China’s peptide pharmaceutical industry.
About Hybio Pharmaceutical
As a national high-tech enterprise listed on the A-share market, Hybio Pharmaceutical focuses on the R&D, production, and sales of innovative drugs. Having been deeply engaged in peptide drugs for more than 20 years, Hybio has a complete preparation pipeline covering mainstream global peptide targets, including but not limited to GLP-1R/GIPR/GCGR triple receptor agonist original innovative drugs, as well as global blockbuster peptide ANDA preparations such as Retatrutide, Tirzepatide, Semaglutide, and Liraglutide. Hybio has obtained nearly 500 authorized patents at China and International. As the world’s first enterprise to obtain FDA approval for the ANDA of GLP-1 daily preparation Liraglutide, Hybio’s products have entered regulated markets in Europe and the United States.
About the Institute of Process Engineering, Chinese Academy of Sciences (IPE-CAS)
Founded in 1958, IPE-CAS aims at the major strategic needs of greenization, intellectualization, and high-endization of the process industry, and is committed to building a new model of integrated development of science, education, and industry from basic research to application. The institute has continuously promoted the reorganization of national key laboratories, forming a new pattern of "3+3 national-level platforms". Focusing on the major national strategic needs in energy, resources, environment, and medicine, it identifies scientific issues based on actual production processes, explores key technologies that determine product quality, yield, cost, and process safety from the perspective of the entire process or system, and breaks through the technical bottlenecks that hinder the industrialization of China’s biotechnology.